title: Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
authors.affiliation: Department of Haematology, Democritus University of Thrace, Alexandroupolis, Greece. annachristof@yahoo.gr
authors.forename: A
authors.initials: A
authors.lastname: Christoforidou
authors.forename: D
authors.initials: D
authors.lastname: Pantelidou
authors.forename: A
authors.initials: A
authors.lastname: Anastasiadis
authors.forename: A
authors.initials: A
authors.lastname: Goutzouvelidis
authors.forename: D
authors.initials: D
authors.lastname: Margaritis
authors.forename: I
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: E
authors.initials: E
authors.lastname: Spanoudakis
authors.forename: V
authors.initials: V
authors.lastname: Kaloutsi
authors.forename: G
authors.initials: G
authors.lastname: Bourikas
authors.forename: C
authors.initials: C
authors.lastname: Tsatalas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D013920:Thrombocythemia, Essential / Q000188:drug therapy*
chemical_list: D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea